Guggenheim Initiates Coverage On Iovance Biotherapeutics with Neutral Rating
Guggenheim analyst Kelsey Goodwin initiates coverage on Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral rating.
Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, and completed the safety observation
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…
Iovance Biotherapeutics Initiates Biologics License Application Submission For Lifileucel In Advanced Melanoma
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that it has initiated a rolling Biologics License Application (BLA)
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Expert Ratings for Iovance Biotherapeutics
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:
Iovance Biotherapeutics: Q2 Earnings Insights
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
7 Analysts Have This to Say About Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter: